Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Desarrollo de terapias inmunes y moleculares dirigidas en oncología: búsqueda de socios con soluciones innovadoras (anticuerpos monoclonales, administración e inyección de medicamentos antitumorales y otras innovaciones relacionadas)

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRFR20160614001
Publicado:
29/06/2016
Caducidad:
29/06/2017
Resumen:
Un hospital universitario francés ha establecido una estructura de investigación para fomentar el desarrollo de nuevas estrategias terapéuticas en oncología. El hospital busca socios académicos e industriales que hayan generado enfoques farmacológicos y biotecnológicos con el fin de desarrollar conjuntamente un tratamiento locorregional para administrar terapias relacionadas con el sistema inmune directamente en el tumor. El hospital está interesado en establecer acuerdos de cooperación técnica e investigación. La plataforma francesa está abierta a participar en proyectos financiados por la UE.

Details

Tittle:
Development of immune and molecular targeted therapies in oncology : partners with innovative solutions sought (monoclonal antibodies, intratumoral drug delivery and injection, other related innovations)
Summary:
A French University Hospital has set up a research structure to foster the development of innovative therapeutic strategies in oncology. It´s looking for academic and industrial partners which generated pharmacological and biotechnological innovative approaches to co-develop locoregional treatment to deliver immune-related therapies directly in tumor site. Research and technological partnerships are sought. The French platform is open to EU funded projects.
Description:
The main activities of the French research platform include :

i) the promotion of selective cohorts of patients to identify or validate biomarker in medical oncology,

ii) the development of preclinical and early phase clinical studies (phase 0, I and IIR) to investigate the immunological and molecular effect of anti-cancer biotherapies.

The specific advantages of this translational research network relies on :
- A rapid and cost-effective access to cancer patients´ derived samples including plasma, peripheral blood mononuclear cells, tumors (fresh material isolated during surgery or biopsies), DNA, ctDNA.
- A multidisciplinary network of investigators including surgeons, medical oncologists, molecular biologists, immunologists, pathologists, as well as specialists of quality of life.
- The involvement of key opinion leader medical oncologists highly committed in research development and clinical trial promotion. They specialise in breast cancers,gastrointestinal cancers, lung cancers and of an internationally recognized biostatistical and methodolical team.

Example of achievements:
- Development of a new bioassay to monitor specific immune responses in cancer patients based on telomerase antigens and allowing the characterization of TH1 CD4+ T cell immunity
- Development of a new vaccine to promote CD4 T cell immunity in cancer patients
- Production of monoclonal antibodies (mouse, Lama, phage display technology) and identification of new prognostic models : a new biological scoring system based on mesothelin, syndecan and angiopoietin 2 was proposed in colon cancers and validated in a specific cohort of 250 patients promoted by our platform

The research network has the objective to develop locoregional treatment to deliver immune-related therapies directly in tumor site.

Technical Specification or Expertise Sought:
Partnerships with research units or biotechnological companies which generated innovative approaches are sought to :
- link pharmacologically active compounds on monoclonal antibodies in the context of antibody drug conjugate approaches.
- inject pharmacological agent by intratumoral route.
- modulate specific anti-tumor immune responses.

Partner sought

Type and Role of Partner Sought:
Biotechnological Research units that develop innovative approaches for intratumoral drug delivery

Biotechnological companies :
- Companies producing monoclonal antibodies
- Companies developing technological tools for drug-monoclonal antibodies linking
- Companies developing devices to promote intratumoral drug delivery
- Companies producing cytotoxic agents or vectors to inject intratumorally

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French